NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Lakewood-Amedex Biotherapeutics, Inc. (LABT) Stock Analysis

Lakewood-Amedex Biotherapeutics, Inc. (LABT) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

LABT

$0.47

−$0.11 (−19.31%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare LABT with… →

LABT Key Statistics

As of Oct 21, 2026
Trading
Open
$0.55
Previous Close
$0.58
Day's Range
0.43–0.58
52-Week Range
0.43–98.20
Volume
621.89K
Valuation
Market Cap
$1.10M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−8.83
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$3.85M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
2.37M
Dividend and dates
Avg Volume
2.48M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

Lakewood-Amedex Biotherapeutics, Inc. (LABT) has a market capitalization of $1.10M.

In fiscal 2025, LABT reported revenue of $0.00.

LABT Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$3.85M—
2024$0.00−$4.86M—
2023$0.00−$8.28M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$3.77M−$3.85M—
2024$0.00—−$4.03M−$4.86M—
2023$0.00—−$8.64M−$8.28M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 15 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Lakewood-Amedex Biotherapeutics, Inc. (LABT) is capitalised at $1.10M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 5 employees.

The 52-week range on file runs from $0.43 to $98.20. The most recent close on file for LABT is $0.47, dated October 21, 2026. That is −$0.11 (−19.31%) against the previous close. The latest close sits 8.02% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $3.85M. Earnings per share on a trailing basis come to −8.83.

Across the 3 fiscal years on file, revenue moves from $0.00 in 2023 to $0.00 in 2025. Of those 3 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Growth & Income

No dividend is on file for LABT.

So far in 2026 the total return is −99.46%.

Peer Comparison

Lakewood-Amedex Biotherapeutics, Inc. (LABT) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Lakewood-Amedex Biotherapeutics, Inc. LABT $1.10M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Lakewood-Amedex Biotherapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Lakewood-Amedex Biotherapeutics, Inc.

Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs. It also develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers, which is in Phase 2b clinical trial. The company was formerly known as Lakewood-Amedex Inc. and changed its name to Lakewood-Amedex Biotherapeutics, Inc. in June 2025. Lakewood-Amedex Biotherapeutics, Inc. was incorporated in 2006 and is headquartered in University Park, Florida.

Visit website →